Despite resistance to endocrine therapies, the ER pathway remains central to oncogenesis, and is thus a key target for developing new therapeutics to manage ER+/HER2- advanced breast cancer [8, 12]. This evidence concerns the gene ERBB2 and breast carcinoma.